Global RNA Therapeutics Market is Expected to Surpass USD 50 Billion Mark by 2034 | DelveInsight

The RNA therapeutics market is experiencing significant growth, driven by increasing investments in RNA-based drug development and advances in delivery technologies. The expanding application of mRNA, small interfering RNA (siRNA), and antisense oligonucleotides (ASOs) across cancer, genetic disorders, and infectious diseases is further supporting market expansion. Growing clinical trial activity and rising regulatory approvals are strengthening the commercial potential of RNA therapies. In addition, improvements in lipid nanoparticles and other delivery platforms are enhancing treatment efficacy and broadening the therapeutic applications of RNA-based medicines.

New York, USA, Oct. 08, 2026 (GLOBE NEWSWIRE) -- Global RNA Therapeutics Market is Expected to Surpass USD 50 Billion Mark by 2034 | DelveInsight

The RNA therapeutics market is experiencing significant growth, driven by increasing investments in RNA-based drug development and advances in delivery technologies. The expanding application of mRNA, small interfering RNA (siRNA), and antisense oligonucleotides (ASOs) across cancer, genetic disorders, and infectious diseases is further supporting market expansion. Growing clinical trial activity and rising regulatory approvals are strengthening the commercial potential of RNA therapies. In addition, improvements in lipid nanoparticles and other delivery platforms are enhancing treatment efficacy and broadening the therapeutic applications of RNA-based medicines.

DelveInsight’s RNA Therapeutics Market Insights report provides the current and forecast market analysis, individual leading RNA therapeutics companies’ market shares, challenges, RNA therapeutics market drivers, barriers, trends, and key RNA therapeutics companies in the market.

RNA Therapeutics Market Summary

• 2025 RNA Therapeutics Market Size: USD 19.7 Billion
• 2034 Projected RNA Therapeutics Market Size: USD 56 Billion
• RNA Therapeutics Market Growth Rate (2026-2034): ~13% 
• Largest RNA Therapeutics Market: North America
• Largest Type Segment: mRNA Vaccines Category
• Key Companies in the RNA Therapeutics Market: Pfizer Inc. (BioNTech), Moderna, Dynavax Technologies, Alnylam Pharmaceuticals, Novartis, Biogen, Ionis Pharmaceuticals, Sarepta Therapeutics, Nippon Shinyaku, Ionis Pharmaceuticals, Bausch + Lomb, Gennova Biopharmaceuticals, DAIICHI SANKYO COMPANY, LIMITED, Arcturus Therapeutics, Inc., Biogen, NS Pharma, Inc., Eyetech Pharmaceuticals, and others. 

To read more about the future of the RNA therapeutics market, get a snapshot @ https://www.delveinsight.com/report-store/rna-therapeutics-market

Key Factors Contributing to the Rise in Growth of the RNA Therapeutics Market

• Growing Adoption of mRNA-Based Therapies: The successful development and commercialization of mRNA vaccines have demonstrated the therapeutic potential of RNA technologies. This has encouraged pharmaceutical companies to expand mRNA research into oncology, infectious diseases, rare disorders, and other therapeutic areas.
• Rising Prevalence of Chronic and Genetic Diseases: The increasing burden of cancer, cardiovascular disorders, metabolic diseases, and rare genetic conditions is driving demand for innovative treatment approaches. RNA therapeutics can target disease pathways at the genetic or molecular level, creating opportunities for conditions with limited treatment options.
• Advancements in RNA Delivery Technologies: Improvements in lipid nanoparticles, conjugated delivery systems, and other RNA delivery platforms are enhancing the stability, cellular uptake, and targeted delivery of RNA molecules. These advances are helping overcome major limitations associated with earlier RNA-based approaches.
• Expansion of the RNA Therapeutics Pipeline: Pharmaceutical and biotechnology companies are rapidly expanding pipelines involving mRNA, small interfering RNA (siRNA), antisense oligonucleotides (ASOs), and other RNA modalities. Increasing clinical-stage activity is broadening the potential applications of RNA therapeutics across multiple disease areas.
• Increasing Investment in RNA Research and Development: Venture capital, pharmaceutical partnerships, government funding, and strategic investments are supporting the development of RNA platforms and manufacturing capabilities. Rising investment is accelerating discovery programs, clinical development, and commercialization efforts.
• Growing Applications in Oncology: RNA technologies are increasingly being investigated for cancer vaccines, immune modulation, gene silencing, and personalized therapies. The ability to design RNA molecules against specific molecular targets is creating opportunities for precision oncology and individualized treatment approaches.
• Advances in RNA Manufacturing and Production: Improvements in large-scale RNA synthesis, purification, formulation, and quality-control processes are supporting the transition of RNA candidates from research to commercial production. More efficient manufacturing is also helping improve scalability and reduce production-related challenges.
• Increasing Use of Personalized Medicine: RNA therapeutics can be designed or modified according to specific genetic and molecular characteristics of diseases. This compatibility with precision medicine is encouraging their development for patient-specific therapies, particularly in oncology and genetic disorders.
• Supportive Regulatory Environment: Regulatory approvals of innovative RNA-based products have provided greater validation of the technology and encouraged further development. Regulatory pathways and incentives for rare diseases and breakthrough therapies are also supporting investment in novel RNA platforms.
• Strategic Partnerships and Licensing Activities: Collaborations between biotechnology companies, pharmaceutical firms, academic institutions, and technology providers are facilitating access to RNA platforms, delivery technologies, and manufacturing capabilities. Such partnerships are helping accelerate clinical development and commercial expansion.
• Growing Interest in Rare and Genetic Diseases: RNA-based approaches can modulate gene expression or address disease-causing genetic mechanisms, making them attractive for rare and inherited disorders. Increasing investment in these areas is expanding the addressable market for RNA therapeutics.

Get a sneak peek at the RNA therapeutics market dynamics @ RNA Therapeutics Market Trends

Regional RNA Therapeutics Market Insights

North America

• North America held the largest share of the RNA therapeutics market, accounting for approximately 45% of the global market in 2025. 
• The region’s leading position is attributed to its well-developed biopharmaceutical ecosystem, substantial R&D investments, and rapid adoption of advanced genetic medicine technologies. 
• The presence of major pharmaceutical and biotechnology companies, established regulatory frameworks, and early availability of innovative therapies further drives market expansion. 
• Moreover, rising government support for biomedical research and robust clinical trial activity in the United States and Canada are expected to strengthen North America’s leadership in RNA-based drug development and commercialization.

Europe

• The RNA therapeutics market in Europe is experiencing robust and sustained growth, supported by increasing regulatory backing from the European Medicines Agency (EMA), the rapid expansion of mRNA-based infectious disease programs, and growing late-stage clinical development activity across respiratory and viral diseases. 
• The region has built a strong foundation for RNA therapeutics through earlier approvals of COVID-19 mRNA vaccines, including Moderna’s Spikevax, which received EMA authorization in January 2021 and marked a significant milestone in the large-scale adoption of RNA technologies across Europe. 
• Since then, the region has continued to expand its RNA therapeutic landscape through updated vaccines, new indications, and next-generation platforms. 
• In July 2025, for instance, the EMA recommended an updated authorization for Moderna’s Spikevax targeting the LP.8.1 COVID-19 variant for the 2025–2026 vaccination season, demonstrating continued regulatory support for advancing mRNA vaccine technologies. 
• More recently, in February 2026, the EMA recommended approval of Moderna’s combined COVID-19 and influenza mRNA vaccine, mCombriax, for adults aged 50 years and older, highlighting growing momentum toward combination RNA-based immunization approaches.
• In parallel with commercial developments, Europe is witnessing significant clinical research activity involving RNA-based therapies and vaccines for infectious and respiratory diseases. 
• Moderna continues to advance late-stage clinical programs, including Phase 3 studies of its seasonal influenza mRNA vaccine candidate, mRNA-1010, as well as combination respiratory vaccines, with clinical trials being conducted at European sites during 2025–2026. 
• GSK plc has also progressed its mRNA-based influenza vaccine candidate into late-stage development following encouraging mid-stage results that demonstrated strong immune responses among both younger and older adults, further strengthening Europe’s position in next-generation vaccine innovation. 
• Meanwhile, companies such as Arcturus Therapeutics, Inc. are broadening RNA research in the region through self-amplifying mRNA vaccine platforms, including pandemic influenza (H5N1) candidates that entered Phase 1 development in 2025.
• Overall, strong regulatory support, the growing number of approvals for updated and combination mRNA vaccines, and an expanding clinical development pipeline are collectively driving the growth of Europe’s RNA therapeutics market. 
• These factors are reinforcing the region’s role as a key and rapidly expanding market for next-generation RNA-based therapeutic and vaccine technologies.

Asia-Pacific

• The Asia Pacific region is emerging as a key growth engine for the RNA therapeutics market, supported by strong government backing, expanding biotechnology infrastructure, large patient populations, and a rapidly growing clinical trial landscape. 
• Countries including China, Japan, South Korea, Singapore, and India are making substantial investments in mRNA, siRNA, and antisense RNA technologies to strengthen domestic biopharmaceutical capabilities and enhance pandemic preparedness. 
• The region also benefits from cost-effective manufacturing capabilities, a well-established contract development and manufacturing organization (CDMO) ecosystem, and increasing collaborations between multinational pharmaceutical companies and local biotechnology firms. 
• These factors are accelerating the development and commercialization of RNA-based therapies. Recent market insights indicate that APAC represents the fastest-growing regional market for RNA therapeutics, with growth particularly supported by infectious disease applications and government-funded research programs focused on nucleic acid medicines, especially in China and Japan.
• The region is also experiencing a notable increase in clinical trial activity across oncology, infectious diseases, and rare genetic disorders, further reinforcing its expanding role in the global RNA therapeutics landscape. 
• In China, several mRNA-based clinical trials have received approval, including investigational RNA-based cancer therapies such as CSPC Pharmaceutical Group’s SYS6020, which entered human trials in 2024 for oncology and autoimmune applications. 
• This development reflects the growing regulatory acceptance and clinical application of RNA technology platforms. 
• Meanwhile, Japan is progressing multiple next-generation RNA and gene therapy programs through robust academic–industry partnerships and government-supported biotechnology initiatives centered on personalized medicine and regenerative therapies. 
• India is likewise establishing itself as an important hub for vaccine research and development and large-scale manufacturing, supported by its expanding biotechnology industry and growing network of contract research organizations.

To know more about why North America is leading the market growth in the RNA therapeutics market, get a snapshot of the RNA Therapeutics Market Analysis

Recent Developmental Activities in the RNA Therapeutics Market

• In September 2026, UTR Therapeutics Inc., a biotechnology company developing clinical trial-ready RNA therapeutics aimed at targeting previously undruggable proteins, announced that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation (ODD) to 3′UTRMYCN M1-14 (UTRxMYCN M1-14) for the treatment of soft tissue sarcoma, including rhabdomyosarcoma (RMS). The FDA also granted Rare Pediatric Disease Designation (RPDD) to the therapy for the treatment of rhabdomyosarcoma.
• In September 2026, 4BIO Capital announced that it led a EUR 40 million seed financing round for Aptadir Therapeutics (Aptadir). The financing will support the advancement of Aptadir’s pipeline of disease-modifying investigational RNA therapeutics, including its lead program, CAP1-FMR1, which is being developed for the treatment of Fragile X Syndrome. Aptadir’s proprietary technology is built on the discovery of a novel class of RNAs capable of selectively preventing aberrant DNA methylation at the level of individual genes.
• In September 2026, Arcturus Therapeutics Holdings Inc. reported encouraging interim Phase 2 results for ARCT-810 in patients with ornithine transcarbamylase (OTC) deficiency. The company also unveiled LUNAR 2.0™, its next-generation mRNA delivery platform, along with additional liver-focused pipeline programs.
• In August 2026, Rznomics Inc. announced that it will join Lilly Gateway Labs (LGL) in San Diego, California.
• In August 2026, Amplitude Therapeutics announced a strategic research collaboration and licensing agreement with Eli Lilly and Company to advance the discovery and development of taRNA-based vaccine candidates for infectious diseases. The initial collaboration will target undisclosed infectious disease vaccine programs addressing areas of significant unmet need, while Lilly will have the option to expand the partnership to include up to two additional infectious disease targets.
• In July 2026, miRecule, Inc. announced a strategic research collaboration with Rio Biofarma Brasil Ltda., a subsidiary of EMS S.A., Brazil’s largest pharmaceutical company. The collaboration aims to advance the co-development of peptide-mediated delivery technologies designed to enhance the targeted delivery of RNA therapeutics to extra-hepatic tissues, with potential applications across a broad spectrum of disease areas.
• In May 2026, EnPlusOne Biosciences, Inc., a biotechnology company focused on advancing enzymatic technologies for RNA therapeutic discovery and development, announced plans to showcase new research findings and recent advances in enzymatic RNA synthesis at two major industry conferences in Boston during the month.

What are RNA Therapeutics?

RNA therapeutics are a class of medicines that use ribonucleic acid (RNA) molecules to regulate gene expression, produce therapeutic proteins, or silence disease-causing genes. Unlike conventional drugs that primarily target proteins or cellular pathways, RNA-based therapies can act at the genetic and molecular level, offering a broader approach to treating diseases with previously difficult-to-drug targets. Major types include messenger RNA (mRNA), small interfering RNA (siRNA), antisense oligonucleotides (ASOs), microRNA-based therapies, and RNA aptamers. mRNA therapeutics provide cells with instructions to produce specific proteins, while siRNA and ASOs can reduce or modify the expression of selected genes. Advances in RNA sequence design, chemical modification, and delivery technologies such as lipid nanoparticles and conjugated delivery systems have improved the stability, specificity, and therapeutic potential of these medicines. RNA therapeutics are being investigated and developed across a wide range of indications, including genetic disorders, cancer, cardiovascular diseases, infectious diseases, metabolic conditions, and neurological disorders, making them an increasingly important area of modern drug development.

RNA Therapeutics Market Report Metrics	Details
Coverage	Global
Study Period	2023–2034
RNA Therapeutics Market CAGR	~12%
RNA Therapeutics Market Size by 2034	USD 56 Billion
Key RNA Therapeutics Companies	Pfizer Inc. (BioNTech), Moderna, Dynavax Technologies, Alnylam Pharmaceuticals, Novartis, Biogen, Ionis Pharmaceuticals, Sarepta Therapeutics, Nippon Shinyaku, Ionis Pharmaceuticals, Bausch + Lomb, Gennova Biopharmaceuticals, DAIICHI SANKYO COMPANY, LIMITED, Arcturus Therapeutics, Inc., Biogen, NS Pharma, Inc., Eyetech Pharmaceuticals, and others

RNA Therapeutics Market Assessment

• RNA Therapeutics Market Segmentation
  • RNA Therapeutics Market Segmentation By Type: RNA Drugs {Antisense Oligonucleotides (ASOs), Small Interfering RNAs (siRNAs), and RNA Aptamers} and mRNA Vaccines
  • RNA Therapeutics Market Segmentation By Indication: Infectious Diseases, Cardiovascular Disorders, Genetic/Rare Disorders, and Ophthalmic Disorders
  • RNA Therapeutics Market Segmentation By Route of Administration: Intravenous (IV), Subcutaneous (SC), Intramuscular (IM), and Intravitreal
  • RNA Therapeutics Market Segmentation By End Users: Hospitals & Clinics and Research & Academic Institutions
  • RNA Therapeutics Market Segmentation By Geography: North America, Europe, Asia-Pacific, and Rest of World
• Porter’s Five Forces Analysis, Product Profiles, Case Studies, KOL’s Views, Analyst’s View

Which MedTech key players in the RNA therapeutics market are set to emerge as the trendsetter explore @ RNA Therapeutics Market Size

Table of Contents 

1	RNA Therapeutics Market Report Introduction
2	RNA Therapeutics Market Executive Summary
3	RNA Therapeutics Market Key Factors Analysis
4	Impact Analysis
5	Regulatory Analysis
6	RNA Therapeutics Market Porter’s Five Forces Analysis
7	RNA Therapeutics Market Assessment
8	Competitive Landscape
9	Startup Funding & Investment Trends
10	RNA Therapeutics Market Company and Product Profiles
11	KOL Views
12	Project Approach
13	About DelveInsight
14	Disclaimer & Contact Us

Interested in knowing the RNA therapeutics market share by 2034? Click to get a snapshot of the Top RNA Therapeutics Companies

Related Reports

mRNA Vaccine and Therapeutics Market

mRNA Vaccine and Therapeutics Market Insight, Competitive Landscape, and Market Forecast – 2034 report delivers an in-depth understanding of market trends, market drivers, market barriers, and key mRNA vaccine and therapeutics companies, including Pfizer Inc., BioNTech SE, Moderna, Inc., Gennova Biopharmaceuticals Limited, GSK plc., Daiichi Sankyo, Arcturus, Boehringer Ingelheim International GmbH, Ethris GmbH, CureVac SE, AIM Vaccine Corporation, Charoen Pokphand Group, Argos Therapeutics Inc., Sanofi, Kernal Biologics Inc., and others.

mRNA Synthesis and Manufacturing Market

mRNA Synthesis and Manufacturing Market Insight, Competitive Landscape, and Market Forecast – 2034 report delivers an in-depth understanding of market trends, market drivers, market barriers, and key mRNA synthesis and manufacturing companies, including Thermo Fisher Scientific Inc., New England Biolabs, TriLink BioTechnologies, DH Life Sciences, LLC, F. Hoffmann-La Roche Ltd., Telesis Bio Inc., Promega Corporation, Jena Bioscience, GenScript, RiboPro, Takara Bio, Lonza, Sigma-Aldrich, Agilent Technologies, Integrated DNA Technologies, Inc., and others.

Global Messenger RNA Market

Global Messenger RNA Market Insight, Epidemiology, and Market Forecast – 2036 report delivers an in-depth understanding of market trends, market drivers, market barriers, and key global messenger RNA companies, including Translate Bio, AstraZeneca, Moderna, CureVac, BioNTech, Roche (Genentech), BioNTech, Sanofi, Moderna, CureVac, Arcturus, and others.

RNA Interference Clinical Trial Analysis 

RNA Interference Pipeline Insight – 2026 report provides comprehensive insights about the pipeline landscape, pipeline drug profiles, including clinical and non-clinical stage products, and the key RNA interference companies, including Silence Therapeutics, Janssen Research & Development, Eli Lilly and Company, Arrowhead Pharmaceuticals, Sylentis, Sirnaomics, Dicerna Pharmaceuticals, Suzhou Ribo Life Science, Alnylam Pharmaceuticals, Suzhou Ribo Life Science, Vir Biotechnology, Arbutus Biopharma, Silenseed, OliX Pharmaceuticals, Bio-Path Holdings, and others.

RNA Competitive Landscape

RNA Competitive Landscape – 2026 report provides comprehensive insights about the pipeline landscape, pipeline drug profiles, including clinical and non-clinical stage products, and the key RNA companies, including Novartis, Arrowhead Pharmaceuticals, Arbutus Biopharm, Dicerna Pharmaceuticals, Inc., SanegeneBio, Alnylam Pharmaceuticals, Eli Lilly and Company, Janssen Pharmaceuticals, Moderna Therapeutics, OliX Pharmaceuticals, ProQR Therapeutics, Fujian Shengdi Pharmaceutical, Silence Therapeutics, WaVe life Sciences, Sirnaomics, ExoRNA Bioscience, Comanche Biopharma, Ractigen Therapeutics, GeneCare Research Institute, Sirana Pharma, DTx Pharma, Aptadel Therapeutics, and others.

About DelveInsight

DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports pharma companies by providing comprehensive end-to-end solutions to improve their performance. Get hassle-free access to all the healthcare and pharma market research reports through our subscription-based platform PharmDelve.

Contact Us

Shruti Thakur 

info@delveinsight.com 

+14699457679